Century Therapeutics, Inc. (IPSC)

NASDAQ: IPSC · IEX Real-Time Price · USD
3.050
-0.040 (-1.29%)
Apr 22, 2024, 4:00 PM EDT - Market closed
-1.29%
Market Cap 198.02M
Revenue (ttm) 2.24M
Net Income (ttm) -136.67M
Shares Out 64.92M
EPS (ttm) -2.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 64,345
Open 3.100
Previous Close 3.090
Day's Range 2.980 - 3.370
52-Week Range 1.280 - 5.510
Beta 1.34
Analysts Strong Buy
Price Target 14.00 (+359.02%)
Earnings Date May 9, 2024

About IPSC

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relaps... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 18, 2021
Employees 152
Stock Exchange NASDAQ
Ticker Symbol IPSC
Full Company Profile

Financial Performance

In 2023, IPSC's revenue was $2.24 million, a decrease of -57.01% compared to the previous year's $5.20 million. Losses were -$136.67 million, 4.38% more than in 2022.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for IPSC stock is "Strong Buy." The 12-month stock price forecast is $14.0, which is an increase of 359.02% from the latest price.

Price Target
$14.0
(359.02% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics

Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based on the potential of its differentiated profil...

11 days ago - GlobeNewsWire

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immu...

14 days ago - GlobeNewsWire

Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

PHILADELPHIA, March 19, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immu...

4 weeks ago - GlobeNewsWire

Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates

- Presented initial data from Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory B-cell lymphomas demonstrating a favorable tolerability profile, early clinical activity and indication that All...

5 weeks ago - GlobeNewsWire

Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Posters will highlight Century's end-to-end cell therapy capabilities including expertise across iPSC reprogramming, gene editing, protein engineering, Allo-Evasion™ technology and computational biolo...

6 weeks ago - GlobeNewsWire

Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun...

2 months ago - GlobeNewsWire

Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits

– Data presented at 65 th ASH Annual Meeting show CNTY-101 was generally well tolerated at Dose Level 1 (100 million cells) in a high-risk, heavily pretreated R/R B-cell lymphoma patient –

4 months ago - GlobeNewsWire

Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

– Represents second IND clearance for CNTY-101, the Company's lead iPSC-derived CD19-targeted CAR NK cell product candidate, and first in an autoimmune and inflammatory disease indication –

4 months ago - GlobeNewsWire

Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus

PHILADELPHIA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun...

4 months ago - GlobeNewsWire

Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference

PHILADELPHIA, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun...

5 months ago - GlobeNewsWire

Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

- Brent Pfeiffenberger, Pharm.D., MBA, appointed Chief Executive Officer of Century Therapeutics - - Initial data from the ongoing Phase 1 ELiPSE-1 trial evaluating CNTY-101 in relapsed or refractory ...

5 months ago - GlobeNewsWire

Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases

PHILADELPHIA and MADISON, Wis., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell...

5 months ago - GlobeNewsWire

Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference

PHILADELPHIA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell th...

7 months ago - GlobeNewsWire

Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

– Company remains on track to report initial data from Schedule A of the ongoing Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas by year end –

9 months ago - GlobeNewsWire

Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

– Preclinical data supporting selection of CNTY-101 as lead product candidate presented at AACR Annual Meeting –

1 year ago - GlobeNewsWire

Century Therapeutics to Present at Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit

PHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell th...

1 year ago - GlobeNewsWire

Century Therapeutics Announces Leadership Changes

–  Lalo Flores, Ph.D., steps down as Chief Executive Officer and member of Board of Directors; Greg Russotti, Ph.D., Chief Technology Officer, assumes role of ad-interim Chief Executive Officer –

1 year ago - GlobeNewsWire

Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates

- Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas underway -

1 year ago - GlobeNewsWire

Century Therapeutics to Present at the AACR Annual Meeting 2023

PHILADELPHIA, March 15, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell th...

1 year ago - GlobeNewsWire

Century Therapeutics to Present at Upcoming Investor Conferences

PHILADELPHIA, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell the...

1 year ago - GlobeNewsWire

Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas

– CNTY-101 is the first cell therapy product candidate engineered with six precision gene edits including a CD19-CAR, Allo-Evasion™ technology, IL-15 cytokine support and a safety switch –

1 year ago - GlobeNewsWire

5 Health Care Stocks That Are Diving - And May Rally

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: FATENVOSSNPXTECH
1 year ago - Benzinga

Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: FATETHRDVERA
1 year ago - Benzinga

Century Therapeutics closes its Seattle hub amid wider cuts, departure of R&D head

Century Therapeutics is closing its Seattle operations as part of a 25% reduction in headcount and a shift in its priorities.

1 year ago - GeekWire

Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026

- Prioritization allows for acceleration of key programs including CNTY-107 in Nectin-4+ tumors, while de-prioritizing further investment in CNTY-103 for glioblastoma -

1 year ago - GlobeNewsWire